find a clinical trial
If you have any questions or are interested in participating in one of our Clinical Trials, please take note of the associated protocol number and contact our team at 201-518-3587, or email us.
298
Clinical Trials
Phase 1 Clinical Trials
Phase I/II
Accepting Patients
nct/study# NCT04145622 / DS7300-A-J101
Phase I/II, Two-Part, Multicenter First-In-Human Study Of DS-7300a In Subjects With Advanced Solid Malignant Tumors
Learn More
Phase 1 Clinical Trials
Phase I/II
Accepting Patients
nct/study# NCT04959981 / ERAS-007-02
Phase 1b/2, Open-Label, Multicenter Study Of ERAS-007 In Combination With Other Anti-Cancer Therapies In Patients With Advanced Non-Small-Cell Lung Cancer (HERKULES-2)
Learn More
Phase 1 Clinical Trials
NA
Accepting Patients
nct/study# NCT04106167 / FT-003
Long-Term, Non-Interventional, Observational Study Following Treatment With Fate Therapeutics FT500 Cellular Immunotherapy
Learn More
Phase 1 Clinical Trials
Phase I
Accepting Patients
nct/study# NCT03841110 / FT500-101
FT500 As Monotherapy And In Combination With Immune Checkpoint Inhibitors In Subjects With Advanced Solid Tumors (Phase 1)
Learn More
Phase 1 Clinical Trials
Phase I
Accepting Patients
nct/study# NCT04551885 / FT516-102
A Phase I, Open-Label, Multicenter Study Of FT516 In Combination With Monoclonal Antibodies In Subjects With Advanced Solid Tumors
Learn More
Phase 1 Clinical Trials
Phase I/II
Accepting Patients
nct/study# NCT03665285 / NC318-01
A Phase 1/2, Open-Label, Dose-Escalation, Safety And Tolerability Study Of NC318 In Subjects With Advanced Or Metastatic Solid Tumors
Learn Morewe are here for you
For more information or to schedule an appointment,
call 844-346-7222. You can also schedule an appointment by calling the RCCA location nearest you.
Regional Cancer Care Associates is one of fewer than 200 medical practices in the country selected to participate in the Oncology Care Model (OCM); a recent Medicare initiative aimed at improving care coordination and access to and quality of care for Medicare beneficiaries undergoing chemotherapy treatment.